ZA202209565B - Novel immunostimulating il-2 analogs - Google Patents
Novel immunostimulating il-2 analogsInfo
- Publication number
- ZA202209565B ZA202209565B ZA2022/09565A ZA202209565A ZA202209565B ZA 202209565 B ZA202209565 B ZA 202209565B ZA 2022/09565 A ZA2022/09565 A ZA 2022/09565A ZA 202209565 A ZA202209565 A ZA 202209565A ZA 202209565 B ZA202209565 B ZA 202209565B
- Authority
- ZA
- South Africa
- Prior art keywords
- analogs
- interleukin
- immunostimulating
- novel
- novel immunostimulating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200039476 | 2020-03-31 | ||
| PCT/KR2021/004028 WO2021201615A1 (ko) | 2020-03-31 | 2021-03-31 | 신규한 면역 활성 인터루킨 2 아날로그 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202209565B true ZA202209565B (en) | 2023-12-20 |
Family
ID=77930406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/09565A ZA202209565B (en) | 2020-03-31 | 2022-08-26 | Novel immunostimulating il-2 analogs |
Country Status (17)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121713A1 (es) * | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| KR20230095612A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그 |
| KR102445492B1 (ko) * | 2021-12-24 | 2022-09-21 | 엔케이젠 주식회사 | 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법 |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
| IL317511A (en) | 2022-06-16 | 2025-02-01 | Cephalon Llc | IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses |
| CN119790064A (zh) * | 2022-08-23 | 2025-04-08 | 马斯得生物有限公司 | Il2变体和包括该il2变体的蛋白复合体 |
| KR20250126198A (ko) | 2024-02-15 | 2025-08-25 | 한림대학교 산학협력단 | 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3285989A (en) * | 1987-11-25 | 1989-06-14 | Cetus Corporation | Treatment of infections caused by a primary immunodeficiency with interleukin-2 |
| AU627477B2 (en) * | 1988-07-05 | 1992-08-27 | Amgen, Inc. | Interleukin ii analogs |
| CA2019714A1 (en) | 1989-06-27 | 1990-12-27 | Richard A. Chizzonite | Process for the determination of interleukins |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| CZ305123B6 (cs) * | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| KR20070003934A (ko) * | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN1930300A (zh) | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| AU2007201663A1 (en) | 2007-04-16 | 2008-10-30 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| WO2012088446A1 (en) * | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| KR20140106452A (ko) | 2013-02-26 | 2014-09-03 | 한미약품 주식회사 | 신규한 인슐린 아날로그 및 이의 용도 |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| MY186251A (en) | 2014-01-20 | 2021-06-30 | Hanmi Pharm Ind Co Ltd | Long-acting insulin and use thereof |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| CN107148279B (zh) | 2014-10-21 | 2021-09-03 | 赛生药品股份国际有限公司 | 用免疫刺激剂治疗癌症 |
| CN104403004B (zh) * | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| KR20160134989A (ko) | 2015-05-14 | 2016-11-24 | 순천향대학교 산학협력단 | 인간 인터류킨-2 단백질을 포함하는 약학조성물 |
| CN107266553A (zh) * | 2016-04-08 | 2017-10-20 | 南京康志制药有限公司 | 高效人白细胞介素ⅱ突变体融合蛋白及其应用 |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CN110913954A (zh) * | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| JP7356726B2 (ja) * | 2017-09-25 | 2023-10-05 | ディンフー バイオターゲット カンパニー リミテッド | タンパク性ヘテロ二量体及びその使用 |
| US10946068B2 (en) * | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7534215B2 (ja) * | 2018-01-24 | 2024-08-14 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | サイトカイン融合タンパク質 |
| CN108503714A (zh) | 2018-04-10 | 2018-09-07 | 浙江科途医学科技有限公司 | 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用 |
| MX2020012251A (es) * | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| AU2019288496B2 (en) * | 2018-06-22 | 2024-11-21 | Cugene Inc. | Interleukin-2 variants and methods of uses thereof |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| SG11202005873QA (en) * | 2018-09-17 | 2020-07-29 | Gi Innovation Inc | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
| CA3098930A1 (en) * | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| MX2021005708A (es) * | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| US20220025007A1 (en) * | 2018-12-21 | 2022-01-27 | Hanmi Pharm. Co., Ltd. | Novel immunosuppressive interleukin 2 |
| CN111944036B (zh) | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| CN114437198A (zh) | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| BR112022017656A2 (pt) | 2020-03-05 | 2022-10-18 | Univ Leland Stanford Junior | Variantes de il-2 concebidas |
| AR121713A1 (es) * | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
-
2021
- 2021-03-31 AR ARP210100815A patent/AR121713A1/es unknown
- 2021-03-31 TW TW110111922A patent/TWI876021B/zh active
- 2021-03-31 BR BR112022018730A patent/BR112022018730A2/pt unknown
- 2021-03-31 CA CA3266069A patent/CA3266069A1/en active Pending
- 2021-03-31 KR KR1020210042319A patent/KR102545250B1/ko active Active
- 2021-03-31 CN CN202180025732.4A patent/CN115427437B/zh active Active
- 2021-03-31 JP JP2022559531A patent/JP7846627B2/ja active Active
- 2021-03-31 EP EP21781220.5A patent/EP4130027A4/en active Pending
- 2021-03-31 NZ NZ793819A patent/NZ793819A/en unknown
- 2021-03-31 CA CA3169564A patent/CA3169564C/en active Active
- 2021-03-31 PE PE2022001948A patent/PE20221759A1/es unknown
- 2021-03-31 US US17/915,808 patent/US11746137B2/en active Active
- 2021-03-31 IL IL295826A patent/IL295826B2/en unknown
- 2021-03-31 MX MX2022011893A patent/MX2022011893A/es unknown
- 2021-03-31 AU AU2021202825A patent/AU2021202825B2/en active Active
- 2021-03-31 CN CN202410385677.5A patent/CN118271419A/zh active Pending
- 2021-03-31 WO PCT/KR2021/004028 patent/WO2021201615A1/ko not_active Ceased
-
2022
- 2022-06-02 AU AU2022203841A patent/AU2022203841A1/en not_active Abandoned
- 2022-08-26 ZA ZA2022/09565A patent/ZA202209565B/en unknown
- 2022-09-21 CL CL2022002562A patent/CL2022002562A1/es unknown
-
2023
- 2023-06-09 KR KR1020230074093A patent/KR102946368B1/ko active Active
- 2023-07-10 US US18/349,656 patent/US12415842B2/en active Active
- 2023-11-30 JP JP2023202447A patent/JP2024041747A/ja active Pending
-
2026
- 2026-04-07 CL CL2026001105A patent/CL2026001105A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ793819A (en) | Novel immunoactive interleukin 2 analog | |
| WO2020005819A8 (en) | De novo design of potent and selective interleukin mimetics | |
| PH12020550661A1 (en) | Partial agonists of interleukin-2 | |
| AR114445A1 (es) | Conjugados de il-15, y sus usos | |
| MY209471A (en) | Interleukin-2 agents and uses thereof | |
| PH12021551840A1 (en) | Claudin 6 antibodies and uses thereof | |
| AU2019263623A8 (en) | Probiotic Bifidobacterium breve strain and compositions comprising said strain | |
| SG11202000123SA (en) | Lactobacillus plantarum cjlp475 strain having antiviral and immunomodulatory effects and composition comprising the same | |
| IL290535A (en) | Preparations, formulations, production and purification of interleukin | |
| PH12022500004A1 (en) | Il-15 conjugates and uses thereof | |
| MX2023010926A (es) | Novedoso conjugado de analogo de il-2 inmunoestimulante y procedimiento de preparacion del mismo. | |
| ZA202303645B (en) | True human antibody specific for interleukin 1 alpha | |
| MX2023006599A (es) | Metodos de uso de agentes de interleucina-2. | |
| MX2023008598A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
| AU2022299404A1 (en) | Interleukin 15 variants | |
| MX2024001644A (es) | Anticuerpos contra el receptor alfa de la interleucina-4 humana. | |
| MX2022010990A (es) | Variantes dise?adas de il-2. | |
| SG11202000113QA (en) | Composition comprising lactobacillus plantarum cjlp475 strain and lactobacillus plantarum cjlp243 strain and use thereof | |
| IL285584A (en) | Interleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells | |
| MX2023003112A (es) | Constructos de interleucina 15 y metodos de uso. | |
| MX2024010561A (es) | Confiteria. | |
| MX2023009567A (es) | Formulaciones de polipeptidos de union a dr5. | |
| SA521431223B1 (ar) | Angpt2 أجسام مضادة لـ | |
| MX2022004545A (es) | Composiciones de pienso animal y usos de las mismas. | |
| HK40109952A (en) | Interleukin 15 variants |